natgillin/translations-raw huggingface dataset:
AZOPT er ikke vurderet hos patienter med snævervinklet glaukom, og det bør ikke anvendes til disse patienter.
AZOPT has not been studied in patients with narrow-angle glaucoma and its use is not recommended in these patients.
AZOPT indeholder et konserveringsmiddel (benzalkoniumchlorid), som kan give irritation af øjnene og misfarve bløde kontaktlinser.
AZOPT contains a preservative (benzalkonium chloride) which may cause eye irritation and is known to discolour soft contact lenses.
AZOPTs sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of AZOPT in infants, children and adolescents aged 0 to 17 years has not been established.
Aztreonam har kunnet fås som injektion siden 1980’erne som et ”argininsalt”.
Aztreonam has been available as an injection since the 1980s as an ‘arginine salt’.
Aztreonam metaboliseres ikke i udpræget grad.
Aztreonam is not extensively metabolised.
Aztreonamkoncentrationen i ekspektorat fra de enkelte patienter udviste betydelige forskelle.
Individual patients’ sputum aztreonam concentrations exhibited considerable variability.
Aztreonamkoncentrationer i plasma fra de enkelte patienter udviste betydelige forskelle.
Individual patients’ plasma aztreonam concentrations exhibited considerable variability.
B - 1000 Bruxelles Belgien
B-1000 Brussels Belgium
B - 1000 Bruxelles Belgien medinfoeuceemea@shire.com
B - 1000 Brussels Belgium medinfoeuceemea@shire.com
B - 2870 Puurs Belgien
B-2870 Puurs, Belgium
b 1,2 ml = maksimal volumen per hætteglas (Xolair 150 mg).
b 1.2 ml = maximum delivered volume per vial (Xolair 150 mg).
b 388 patienter vurderet i gruppen behandlet med gemcitabin c 404 patienter vurderet i gruppen behandlet med Abraxane/gemcitabin
b 388 patients assessed in gemcitabine-treated group c 404 patients assessed in Abraxane/gemcitabine-treated group
b 48 uger dobbeltblind tenofovirdisoproxilfumarat, efterfulgt af 48 uger open-label.
b 48 weeks of double-blind tenofovir disoproxil fumarate followed by 48 weeks open-label.
b 95 % konfidensinterval for median progressionsfri overlevelsestid. c Baseret på Cox proportionale hazards model, som sammenligner hazard-funktionerne relateret til behandlingsgrupperne, d P-værdien er baseret på en non-stratificeret log-rank-test.
b 95% confidence interval about the median overall survival time. c Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups. d The p-value is based on an unstratified log-rank test.
b 95 % konfidensinterval for median progressionsfri overlevelsestid. c Baseret på Cox proportionale hazards model, som sammenligner hazard-funktionerne relateret til behandlingsgrupperne, stratificeret ved alder (≤75 versus. >75), sygdomspopulation (refraktær over for både lenalidomid og bortezomib versus ikke refraktær over for begge lægemidler) og antal tidligere behandlinger mod myelom (=2 versus. >2). d P-værdien er baseret på en stratificeret log-rank-test med samme stratifikationsfaktorer som for ovenstående Cox-model.
b 95% confidence interval about the median progression free survival time. c Based on Cox proportional hazards model comparing the hazard functions associated with treatment groups, stratified by age (≤75 vs >75),diseases population (refractory to both Lenalidomide and Bortezomib vs not refractory to both drugs), and prior number of anti myeloma therapy (=2 vs >2). d The p-value is based on a stratified log-rank test with the same stratification factors as the above Cox model.
b Analysen omfatter patienter, som fik knoglemarvstransplantationer i denne periode.
bAnalysis includes patients receiving BM transplant during this period
B BETINGELSER ELLER BEGRÆNSNINGER VEDRØRENDE UDLEVERING OG ANVENDELSE
CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
b et primært endepunkt c Roche Cobas Amplicor PCR-assay (LLOQ = 300 kopier/ml)
b a primary endpoint c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
b et primært endepunkt c Roche Cobas Amplicor PCR-assay (LLOQ = 300 kopier/ml)
b a primary endpoint. c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
b f.eks. øget risiko for blå mærker, spontane hæmatomer, hæmoragisk diatese c Identificeret efter markedsføring d Frekvenser fra laboratorieobservationer (Urinsyrestigninger til >øvre normalgrænse fra baseline under eller inden for referenceområde.
b e.g. increased tendency to bruise, spontaneous haematoma, haemorrhagic diathesis c Identified in post-marketing experience d Frequencies derived from lab observations (Uric acid increases to >upper limit of normal from baseline below or within reference range.
b For CP-patienter inkluderes patienter (N), der opnåede eller fastholdt MCyR.
b For CP patients, includes patients (N) who attained or maintained MCyR.
b Frekvens er baseret på laboratorieværdier.
b Frequency is based on laboratory values.
B Hyppigheden for alle ikke almindelige bivirkninger er baseret på data for enkeltstofferne.
B Frequencies of all uncommon adverse reactions were based on the individual mono-components data.
b Indberettet for  2 patienter, der fik KANUMA
b Reported in  2 patients receiving KANUMA
b Indberettet lige hyppigt for patienter, der fik KANUMA og placebo, eller hyppigere for patienter, der fik placebo, under den dobbeltblinde del af LAL-CL02 c Indberettet som en del af en bivirkning hos en enkelt patient, der fik KANUMA i LAL-CL02 d Alder ved første dosis: 4 til 58 år e Indberettet for  2 patienter, der fik KANUMA
b Reported at the same frequency in patients receiving KANUMA or placebo or more frequently in patients receiving placebo during the double-blind period of LAL-CL02 c Reported as part of an adverse reaction in a single patient receiving KANUMA in LAL-CL02 d Age at first dose: 4 to 58 years e Reported in  2 patients receiving KANUMA
B INDLÆGSSEDDEL
PACKAGE LEAFLET
B INDLÆGSSEDDEL (FYLDTE SPRØJTER)
B. PACKAGE LEAFLET (PREFILLED SYRINGE)
b Inklusive (meget almindelig) stomatitis, mundulceration, aftøs stomatitis og (ikke almindelig) gingivalsmerter, glossitis, læbeulceration, tungeulceration c Inklusive (almindelig) udslæt, erytematøst udslæt, erytem og (ikke almindelig) makuløst udslæt, makulopapuløst udslæt, generaliseret udslæt d Hyppigheden er baseret på antallet af kvinder i de samlede data, der var mellem 10 og 55 år, mens de var i behandling
b Includes (very common) stomatitis, mouth ulceration, aphthous stomatitis and (uncommon) gingival pain, glossitis, lip ulceration, tongue ulceration c Includes (common) rash, rash erythematous, erythema and (uncommon) rash macular, rash maculo-papular, rash generalised d Frequency based upon number of women from 10 to 55 years of age while on treatment in the pooled data
B Koncentration af infusionsopløsning er 0,77 mg/ml.
B Infusion solution concentration is 0.77 mg/mL
b L1 protein i form af viruslignende partikler produceret i gærceller (Saccharomyces cerevisiae CANADE 3C-5 (stamme 1895)) ved hjælp af rekombinant DNA- teknologi. c Adsorberet på amorf aluminium hydroxyfosfat-sulfat-adjuvans (225 mikrogram Al)
b L1 protein in the form of virus-like particles produced in yeast cells (Saccharomyces cerevisiae CANADE 3C-5 (Strain 1895)) by recombinant DNA technology c adsorbed on amorphous aluminium hydroxyphosphate sulphate adjuvant (225 micrograms Al)
B LS-gennemsnit og CI baseret på en ANCOVA-model med baseline BCVA-måling som en kovariat, og en faktor for behandlingsgruppe.
B LS mean and CI based on an ANCOVA model with baseline BCVA measurement as a covariate and a factor for treatment group.
b LS-middelværdi (SE). c Non-inferioritet blev testet ved anvendelse af en præspecificeret, fast non-inferioritetsmargin på 4% på dag 28 i cyklus 1. d Estimater blev opnået fra en Cox proportional hazards-regressionsmodel. e P-værdi bestemt ved anvendelse af en log-rank-test.
b LS Mean (SE). c Non-inferiority was tested using a pre-specified, fixed non-inferiority margin of 4% at Day 28 of Cycle 1. d Estimates were obtained from a Cox proportional hazards regression model. e P-value determined using a log-rank test.
b n omfatter alle patienter, som har fået mindst én dags aferese
b n includes all patients who received at least one day of apheresis
b p < 0,001, etanercept vs. placebo c p < 0,01, etanercept vs. placebo
b p < 0.001, etanercept vs. placebo c p < 0.01, etanercept vs. placebo
b p < 0,05 c nominelt signifikant (p < 0,05)
b p < 0.05 c nominally significant (p < 0.05)
b p < 0,05. c Ikke relevant. d p < 0,001.
b p < 0.05. c Not applicable. d p < 0.001.
b p-værdi for tid til forværring baseret på stratificeret log-rank test c p-værdier blev ikke justeret for multiplicitet
b p-value for time to deterioration based on stratified log-rank test c p-values were not adjusted for multiplicity
b p-værdi fra den stratificerede log-rank test; analyse ud fra behandling udelukker opdeling på tidligere behandling; p < 0,0001 c Responspopulation omfatter patienter, som havde målbar sygdom ved baseline og fik mindst 1 dosis studiemedicin. d p-værdi fra Cochran-Mantel-Haenszel chi-square-testen justeret for stratifikationsfaktorer; analyse ud fra behandling udelukker opdeling på tidligere behandling
b p-value from the stratified log-rank test; analysis by line of therapy excludes stratification for therapeutic history; p < 0.0001 c Response population includes patients who had measurable disease at baseline and received at least 1 dose of study medicinal product. d p-value from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors; analysis by line of therapy excludes stratification for therapeutic history
b p-værdi fra den stratificerede log-rank-test; analyse ud fra behandling udelukker stratifikation ifølge tidligere behandling; p < 0,0001 c Responspopulation omfatter patienter, som havde målbar sygdom ved baseline og fik mindst 1 dosis af forsøgslægemidlet. d. p-værdi fra Cochran-Mantel-Haenszel chi-kvadrattest justeret for stratifikationsfaktorer; analyse ud fra behandling udelukker stratifikation ifølge tidligere behandling
b p-value from the stratified log-rank test; analysis by line of therapy excludes stratification for therapeutic history; p < 0.0001 c Response population includes patients who had measurable disease at baseline and received at least 1 dose of study medicinal product. d p-value from the Cochran-Mantel-Haenszel chi-square test adjusted for the stratification factors; analysis by line of therapy excludes stratification for therapeutic history
b p<0,05. c Ikke relevant. d p<0,001.
b p < 0.05. c Not applicable. d p < 0.001.
b p0.001 sammenlignet med placebo c Der er ikke set en signifikant nedsættelse af hyppigheden af hoftefrakturer. d p0.025 sammenlignet med placebo
b p0.001 compared with placebo c A significant reduction in the incidence of hip fractures has not been demonstrated d p0.025 compared with placebo.
b REYATAZ/RTV med tenofovir/emtricitabin (fast dosis på 300 mg/200 mg tabletter en gang dagligt).
b REYATAZ/RTV with tenofovir/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
b REYATAZ/RTV med tenofovirdisoproxilfumarat/emtricitabin (fast dosis på 300 mg/200 mg tabletter en gang dagligt).
b REYATAZ/RTV with tenofovir disoproxil fumarate/emtricitabine (fixed dose 300 mg/200 mg tablets once daily).
b Studiet var designet til at vise ikke dårligere kvalitet.
b The study was designed to show non-inferiority.
b Sygdoms kontrolrate = SD + ORR
b Disease Control Rate = SD+ ORR
b tavst myokardieinfarkt undtaget. c SRI = alvorlig recidiverende iskæmi; RI = recidiverende iskæmi; TIA = transitorisk iskæmisk attak; ATE = arteriel trombotisk hændelse.
bexcluding silent myocardial infarction. cSRI = serious recurrent ischaemia; RI = recurrent ischaemia; TIA = transient ischaemic attack; ATE = arterial thrombotic event.
b) Forberedelse af injektionen
Getting ready to inject
B) Forskel og 95 % CI er beregnet med Mantel-Haenszel-vægtningsskema justeret for region (Nordamerika vs.
B) Difference and 95% CI are calculated using Mantel-Haenszel weighting scheme adjusted for region (North America vs.
B) Forskel og konfidensinterval (CI) beregnes med Cochran-Mantel-Haenszel (CMH)-test justeret for område (Amerika vs. resten af verden for COPERNICUS og Europa vs.
B) Difference and confidence interval (CI) are calculated using Cochran-Mantel-Haenszel (CMH) test adjusted for region (America vs. rest of the world for COPERNICUS and Europe vs.
B) Fuldt analysesæt (FAS), Last Observation Carried Forward (LOCF) for alle analyser bortset fra andel af patienter med bevaret synsstyrke ved uge 52, som er PPS
B) Full Analysis Set (FAS), Last Observation Carried Forward (LOCF) for all analyses except proportion of patients with maintained visual acuity at week 52 which is PPS
b) Ved kontinuerlig indgift
b) By continuous infusion
B,C,E
9.1
B- celle-niveauet normaliseredes hos disse dyr inden for 6 måneder efter fødslen og påvirkede ikke vaccinationsreaktionen.
B cell counts returned to normal in these animals within 6 months of birth and did not compromise the reaction to immunization.
B- lymfocytter er medvirkende til nogle af de symptomer, du har.
B lymphocytes are involved in the cause of some of the symptoms you have.
B-1070 Bryssel Belgien
B-1070 Brussels Belgium
B-1080 Bruxelles B-6900 Marche en Famenne
B-1080 Brussels B-6900 Marche en Famenne
B-1330 Rixensart Belgien
B-1330 Rixensart, Belgium
B-1420 Braine -l´Alleud Belgien
B-1420 Braine l’Alleud Belgium
B-1420 Braine l'Alleud Belgien
B-1420 Braine l'Alleud Belgium
B-1420 Braine-L'Alleud Belgien
B-1420 Braine-L'Alleud Belgium
B-1420 Braine-l’Alleud Belgien
B-1420 Braine- l’Alleud Belgium
B-1420 Braine-l’Alleud Belgien
B-1420 Braine-l’Alleud Belgium
B-1831 Diegem Belgien
B-1831 Diegem Belgium
B-1932 Sint-Stevens-Woluwe België/Belgique/Belgien Tél/Tel: + 32 (0)2 290 52 00 beinfo@grunenthal.com
1932 Sint-Stevens-Woluwe België/Belgique/Belgien
B-2340 Beerse Belgien
2340 Beerse Belgium
B-2340 Beerse Belgique/Belgien Tél/Tel: +32 14 64 94 11
B-2340 Beerse Belgique/Belgien Tél/Tel: + 32 14 64 94 11
B-2870, Puurs Belgien
B-2870 Puurs, Belgium.
B-6900 Marche en Famenne Belgien
B-6900 Marche en Famenne Belgium
B-7860 Lessines Belgien
B-7860 Lessines Belgium
B-8020 Oostkamp Belgien
B-8020 Oostkamp Belgium
B-celle niveauer i spædbørn efter moderen havde været eksponeret for MabThera, er ikke undersøgt i kliniske studier.
B cell levels in human neonates following maternal exposure to MabThera have not been studied in clinical trials.
B-celleniveauer hos spædbørn, efter moderen havde været eksponeret for MabThera, er ikke undersøgt i kliniske studier.
B-cell levels in human neonates following maternal exposure to MabThera have not been studied in clinical trials.
B-celletumorerne omfatter CLL (generelt kendetegnet ved, at cellerne udtrykker et lavere niveau CD20), og non-Hodgkin-lymfomer (hvor >90 % af tumorerne udtrykker CD20 på et højt niveau).
The B cell tumours include CLL (generally associated with lower levels of CD20 expression) and non-Hodgkin's lymphomas (where >90% tumours have high levels of CD20 expression).
B-celleværdier steg til normale niveauer og den immunologiske funktion reetableredes inden for 6 måneder postpartum.
The B cell counts returned to normal levels, and immunologic function was restored within 6 months post-partum.
B-domænet fjernet), og med de samme post-translationelle modifikationer, der findes i molekyler udvundet fra plasma.
B-domain deleted) and similar post-translational modifications to those of the plasma-derived molecule.
B-mode scanning af hjertekamre, i hvile eller med stress: 2 ml.
B-mode imaging of cardiac chambers, at rest or with stress: 2 ml.
B-prækursor-ALL recidiveret efter mindst én induktions- og konsolidationsbehandling eller med refraktær sygdom med > 5 % blastceller i knoglemarv, ECOG-status ≤ 2, forventet levetid ≥ 12 uger, som ikke havde fået autolog HSCT inden for 6 uger inden start af behandling med BLINCYTO, allogen HSCT inden for 3 måneder inden start af behandling med BLINCYTO eller tidligere behandling med BLINCYTO), blev BLINCYTOs sikkerhed og virkning undersøgt.
> 5% blasts in bone marrow, ECOG performance status ≤ 2, life expectancy of ≥ 12 weeks, who did not have autologous haematopoietic stem cell transplantation (HSCT) within 6 weeks prior to start of BLINCYTO treatment, allogeneic HSCT within 3 months prior to start of BLINCYTO treatment, or previous treatment with BLINCYTO), the safety and efficacy of BLINCYTO were evaluated.
B. Hold huden fast sammenklemt, og (1) tryk på og (2) slip umiddelbart efter den grønne knap på toppen af pennen.
B. While holding the pre-filled pen in place, (1) press and (2) 1 press release the green button on top.
B. Hold nålen vandret på linie med pennen når du sætter nålen på (skru eller tryk nålen på afhængig af nåletypen).
Line up the needle with the pen, and keep it straight as you attach it (screw or push on, depending on the needle type).
B. INDLÆGSSEDDEL
PACKAGE LEAFLET
B. Vaccination med Ambirix skal udskydes hos patienter med pludseligt opstået, alvorlig feber.
Vaccination with Ambirix should be postponed in patients with a severe sudden fever.
B.Kasser nålen sikkert, som anbefalet af dit sundhedspersonale.
Dispose of the needle safely, as instructed by your doctor, pharmacist or nurse.
B.Kasser nålen sikkert, som anbefalet af dit sundhedspersonale.
Dispose of the needle safely.
B.Kassér nålen sikkert, som anbefalet af dit sundhedspersonale.
Dispose of the needle safely, as instructed by your doctor, pharmacist or nurse.
B.Tag den ydre nålekapsel af og behold den til at fjerne den brugte nål efter injektionen.
Take off the outer needle cap and keep it to remove the used needle after injection.
B.V. og for legemsoverfladeareal for interferon alfa-2b.
B.V. and by body surface area for interferon alfa-2b.
B//Brisbane/60/2008-lignende stamme (B/Brisbane/60/2008, MEDI 228030) 107,0±0,5 FFU***
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, MEDI 228030) 107.0±0.5 FFU
B/Brisbane/60/2008 - lignende stamme (B/Brisbane/60/2008, vild type) ...............
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) ....................
B/Brisbane/60/2008 - lignende stamme (B/Brisbane/60/2008, vild type) ...............
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) .....................
B/Brisbane/60/2008 - lignende stamme (B/Brisbane/60/2008, vild type)...............15 mikrogram HA** Pr. dosis på 0,1 ml
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type) .......................15 micrograms HA** Per 0.1 ml dose
B/Brisbane/60/2008-lignende stamme (B/Brisbane/60/2008, MEDI 228030) 107,0±0,5 FFU***
B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, MEDI 228030) 107.0±0.5 FFU
B/Massachusetts/2/2012-lignende stamme (B/Massachusetts/2/2012, MEDI 237751) 107,0±0,5 FFU***
B/Massachusetts/2/2012-like strain (B/Massachusetts/2/2012, MEDI 237751) 107.0±0.5 FFU
B/Phuket/3073/2013-lignende stamme (B/Phuket/3073/2013, MEDI 254977) 107,0±0,5 FFU***
B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977) 107.0±0.5 FFU
B/Phuket/3073/2013-lignende stamme (B/Phuket/3073/2013, MEDI 254977) 107.0±0.5 FFU***
B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 254977) 107.0±0.5 FFU
B/Phuket/3073/2013-lignende stamme (B/Utah/9/2014, vildtype) 15 mikrogram HA** pr.
A/California/7/2009 (H1N1)pdm09- like strain (A/Brisbane/10/2010, wild type) 15 micrograms HA
B1) og dernæst trække det i lige linje væk fra sprøjtens cylinder (fig.
Insert the full length of the needle at right angles into the skin fold (picture D).
B12-vitaminmangel
Vitamin B12 deficiency
B1330 Rixensart, Belgien
B-1330 Rixensart, Belgium
B2).
Picture D
b: 2 morgen, 3 aften
b: 2 morning, 3 evening
B: Blanding af det anviste antal breve REYATAZ oralt pulver med væske som f.eks. mælk eller vand i en lille drikkekop:
B: To mix the recommended number of REYATAZ oral powder sachets with a beverage such as milk or water in a small drinking cup:
B: Lad injektionssprøjten få stuetemperatur
Let the syringe warm up
b: n = antallet af respondenter/antal patienter med given genotype, og fastsat behandlingsvarighed. c: Patienter med genotype 3 lav viral load (< 600.000 IE/ml) skulle modtage 24 ugers behandling mens de med genotype 3 og høj viral load (≥ 600.000 IE/ml) skulle modtage 48 uger behandling.
b: n = number of responders/number of subjects with given genotype, and assigned treatment duration. c: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/ml) were to receive 48 weeks of treatment.
b: n = antallet af respondenter/antal patienter med given genotype, og fastsat behandlingsvarighed. c: Patienter med genotype 3 lav virusbelastning (< 600.000 IE/ml) fik 24 ugers behandling, mens de med genotype 3 og høj virusbelastning (≥ 600.000 IE/ml) fik 48 ugers behandling.
b: n = number of responders/number of subjects with given genotype, and assigned treatment duration. c: Patients with genotype 3 low viral load (< 600,000 IU/ml) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/ml) were to receive 48 weeks of treatment.
b: n = antallet af respondenter/antal patienter med given genotype, og fastsat behandlingsvarighed. c: Patienter med genotype 3 og lav virusbelastning (< 600.000 IE/ml) skulle have behandling i 24 uger, mens patienter med genotype 3 og høj virusbelastning (≥ 600.000 IE/ml) skulle have behandling i 48 uger.
b: n = number of responders/number of subjects with given genotype, and assigned treatment duration. c: Patients with genotype 3 low viral load (< 600,000 IU/mL) were to receive 24 weeks of treatment while those with genotype 3 and high viral load (≥ 600,000 IU/mL) were to receive 48 weeks of treatment.
B: p=0,002, Enbrel vs. placebo
b: p = 0.002, Enbrel vs. placebo
B=bortezomib; Dx=dexamethason; T=thalidomid
B=bortezomib; Dx=dexamethasone; T=thalidomide
Babesia rossi kulturer.
Babesia rossi cultures
Babyer
Baby
Baclofen (en medicin med afslappende effekt på musklerne)
Baclofen (a muscle relaxant)
Bacteroides fragilis gruppen†
Bacteroides fragilis group
Bacteroides fragilis og arter i B. fragilis-gruppen*
Bacteroides fragilis and species in the B. fragilis Group
Badning eller indsæbning af hunden inden for henholdsvis 8/24 timer efter behandling kan reducere virkningen af produktet.
Immersion of the animal in water or shampooing within 24 hours after treatment may reduce the efficacy of the veterinary medicinal product.
Badning med shampoo eller vand umiddelbart efter behandling eller hyppig badning med shampoo kan reducere effektens varighed.
However, shampooing or immersion of the animal in water directly after treatment or frequent shampooing may reduce the duration of activity.
Badning, svømning eller brusebad påvirker ikke plasteret.
Bathing, swimming or showering should not affect the patch.
Bag på bag på armen.
Back of thigh, or in the back of your arm.
Bag på eller bag på armen.
Back of your thigh, or in the back of your arm.
baggrund af historiske data kan der forventes en
on historical data, a decrease in etravirine
BAGGRUND FOR EN YDERLIGERE FORNYELSE AF MARKEDSFØRINGSTILLADELSEN
GROUNDS FOR ONE ADDITIONAL RENEWAL
Baggrundsbehandlingen bestod af diæt og motion, metformin, et sulfonylurea-præparat, et thiazolidindion-præparat eller en kombination af orale glucosesænkende lægemidler.
Background therapies included diet and exercise, metformin, a sulphonylurea, a thiazolidinedione or a combination of oral glucose-lowering agents.
Baggrundsinformation om mycophenolatmofetils teratogenicitet og mutagenicitet hos mennesker.
Background information on mycophenolate mofetil teratogenicity and mutagenicity in humans.
Baggrundsinformation om retikulin i knoglemarven (dvs. baggrundshyppigheden af retikulin i knoglemarven hos ITP-patienter samt den observerede forekomst af og mulige virkningsmekanisme for retikulinaflejring ved behandling med Revolade).
Background information on reticulin in the bone marrow (i.e. background rates of reticulin in bone marrow in ITP patients and the observed incidence and potential mechanism of action of reticulin deposition in response to Revolade).
Baggrundstællinga
Background counta
BAGPÅ - Aranesp startguide:
BACK- Aranesp getting started guide:
BAGPÅ - Nespo startguide:
BACK- Neso getting started guide: